NEWS
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Just Updated: Compare Your Institution (Live Data)
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025 (Updated Today)
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
For Students
local_fire_department
Country Reports
person
Find a Professional
nadine hein
Australian National University - Canberra / Australia
Natural Sciences / Molecular Biology & Genetics
AD Scientific Index ID: 128041
Registration, Add Profile,
Premium Membership
Get Your Global Impact Certificate
Ranking &
Analysis
Job
Experiences
Education
Information
Published Books
Book Chapters
Articles
Presentations
Lessons
Projects
Co-Authors
Subject Leaders
Editorship, Referee &
Scientific Board
Patents /
Designs
Academic Grants
& Awards
Artistic
Activities
Certificate / Course
/ Trainings
Association &
Society Memberships
Contact, Office
& Social Media
person_outline
nadine hein's MOST POPULAR ARTICLES
1-)
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53 Cancer cell 22 (1), 51-65, 2012
2-)
The nucleolus: an emerging target for cancer therapy Trends in molecular medicine 19 (11), 643-654, 2013
3-)
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation Proceedings of the National Academy of Sciences 107 (1), 58-63, 2010
4-)
Identification of Burkholderia pseudomallei Genes Required for the Intracellular Life Cycle and In Vivo Virulence Infection and immunity 74 (6), 3576-3586, 2006
5-)
First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study Cancer discovery 9 (8), 1036-1049, 2019
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept